News

€10m for crop research
Enlarge image

FundingFranceGermanyPortugalSpain

€10m for crop research

31.07.2012 - The transnational plant genome research funding initiative PLANT-KBBE has published its 6th call: €10m will be provided for crop breeding projects.

The acronym PLANT-KBBE stands for: 'Transnational PLant Alliance for Novel Technologies – towards implementing the Knowledge-Based Bio-Economy in Europe' (PLANT-KBBE) and represents an international funding initiative between France, Spain, Germany and Portugal. National funding partners are the Ministry of Research and Innovation (DGRI) in France, represented by the national funding agency ANR (Agence Nationale de la Recherche), the Ministry of Economy and Competitiveness (MINECO) in Spain, the Federal Ministry of Education and Research (BMBF) in Germany and the Portuguese national funding agency FCT (Fundação para a Ciênca e a Tecnologia). 

Purpose of the call, which is the 6th transnational ‘Call for Proposals’ (‘Food & Feed: crop yields and nutrition security in the context of climate change‘) is the accelerated implementation of practical applications based on achieved scientific findings, accompanied with an immediate transfer of research results in new processes, products and services. The programme targets projects  that are based on the following general research themes: Yield stability, plant health, adaptation to pressures from the environment and phenotypic plasticity. 

The higher purpose of the PLANT-KBBE funding initiative is the implementation, as well as continuation, of transnational research projects between research groups and enterprises of the partner countries mentioned above, with the objective of further deepening the already existing cooperation between economy and science in and between these countries. In the framework of PLANT-KBBE, SMEs are  particularly addressed. The funding partners also intend to support such multi-disciplinary R&D-activities in the context of public-private-partnerships, integrating other research fields apart from plant biotechnology. Full proposals are to be submitted by October 15.

http://www.european-biotechnology-news.com/news/news/2012-03/eur10m-for-transnational-crop-research.html

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • BIOFRONTERA2.52 EUR2.44%
  • SYNGENTA319.30 CHF2.34%

FLOP

  • SARTORIUS97.00 EUR-3.67%
  • CO.DON2.51 EUR-2.33%
  • EVOLVA1.28 CHF-2.29%

TOP

  • CYTOS0.28 CHF86.7%
  • EPIGENOMICS5.15 EUR50.6%
  • STRATEC BIOMEDICAL48.50 EUR29.3%

FLOP

  • BIOFRONTERA2.52 EUR-13.4%
  • CO.DON2.51 EUR-11.0%
  • ADDEX3.07 CHF-10.8%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 20.11.2014